-
丙酮酸激酶是糖酵解途径的一个关键酶,它有4种不同的同工酶,分别为L型、R型、M1型和M2型。这4种同工酶的表达具有组织特异性。正常情况下,上述4种亚型都以高活性的四聚体形式存在。但在肿瘤细胞中,M2型丙酮酸激酶(M2-type pyruvate kinase,M2-PK)主要以低活性的二聚体形式存在,成为肿瘤细胞特征性的糖代谢酶,因此称为肿瘤M2-PK。
研究表明,在肾细胞癌、胃肠道癌等患者的血浆中,肿瘤标志物M2-PK水平明显升高[2-3]。但目前市场上检测M2-PK使用的都是进口试剂,检测成本很高,因此,开发国内自产的试剂盒十分必要,是广大医生的迫切需求。
肿瘤M2型-丙酮酸激酶单克隆抗体的制备及免疫放射分析方法的建立
Preparation of the monoclonal antibodies against tumor M2-type pyruvate kinase and establishment of immunoradiometric analysis for detection
-
摘要:
目的 制备肿瘤M2型-丙酮酸激酶(M2-PK)单克隆抗体,并建立免疫放射分析的检测方法。 方法 用肿瘤M2-PK抗原免疫小鼠,经细胞融合及筛选后得到一对单克隆抗体,建立免疫放射分析的方法,并评价该检测方法的灵敏度、特异度及精密度。 结果 获得了1A6和3F8两株效价高、特异度好的单克隆抗体,建立了双抗体夹心免疫放射分析方法。该检测方法的分析灵敏度为2 U/ml,临床灵敏度和特异度分别为70.5%和89.0%,提供的M2-PK的正常参考值范围是 < 14.8 U/ml,批内不精密度 < 5%,批间不精密度 < 10%。 结论 建立的双抗体夹心免疫放射分析法可用于体检筛查及肿瘤患者的早期诊断,做到尽早治疗,提高患者的生存质量。 Abstract:Objective To produce monoclonal antibodies against tumor M2-type pyruvate kinase(M2-PK), and to establish immunoradiometric analysis for detection. Methods The BALB/c mice were immunized with M2-PK antigen. Monoclonal antibodies were generated after cell fusion and screening. Established detection method of immunoradiometric analysis and then evaluated its sensitivity, specificity and coefficient of variation. Results Two monoclonal antibodies(1A6 and 3F8)with high-titer and high-specificity were generated and detection method of immunoradiometric analysis was established. The analytical sensitivity of immunoradiometric analysis was 2 U/ml, while its clinical sensitivity and specificity was 70.5% and 89.0% respectively. The reference value of M2-PK level was less than 14.8 U/ml according to immunoradiometric analysis. Intra-assay coefficient of variation was less than 5%, while inter-assay coefficient of variation was less than 10%. Conclusion This sensitive immunoradiometric analysis can be used in early diagnosis of tumor and physical examination. -
Key words:
- Pyruvate kinase /
- Antibodies, monoclonal /
- Immunoradiometric assay
-
[1] Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol, 2005, 15(4): 300-308. [2] Hardt PD, Ewald N. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Expert Rev Mol Diagn, 2008, 8(5): 579-585. doi: 10.1586/14737159.8.5.579 [3] Weinberger R, Appel B, Stein A, et al. The pyruvate kinase isoenzyme M2(Tu M2-PK) as a tumour marker for renal cell carcinoma. Eur J Cancer Care (Engl), 2007, 16(4): 333-337. doi: 10.1111/j.1365-2354.2006.00753.x [4] 丁志祥, 解东涯, 杨春秀, 等.血浆TU M2-PK检测对肺癌的诊断价值.第二军医大学学报, 2006, 27(2): 219-220. doi: 10.3321/j.issn:0258-879X.2006.02.028
[5] Kumar Y, Tapuria N, Kirmani N, et al. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol, 2007, 19(3): 265-276. doi: 10.1097/MEG.0b013e3280102f78 [6] 禹立霞, 刘宝瑞, 王立峰, 等.胃肠肿瘤术后Tu M2-PK含量的变化.实用医技杂志, 2006, 13(3): 350-352. doi: 10.3969/j.issn.1671-5098.2006.03.013